Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Individually titrated doses on daily basis
Department of clinical oncology, Næstved-Roskilde Hospital
Næstved, Denmark
Energy and protein intake
Dietary history (% of estimated needs - NRS 2002)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Lean body mass
Bioimpedance (% of body weight, kg)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 1
VAS (cm on 10 cm scale)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 2
Dietary history (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 3
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 4
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Quality of life 1
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Quality of life 2
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quality of life 3
VAS (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 1
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 2
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 3
VAS (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Mortality (8 weeks)
Patient records, national register
Time frame: 8 weeks